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Abstract: Colorectal carcinoma remains one of the most prevalent cancers with high morbidity and mortality. 
Arginine ADP-ribosyltransferase 1 (ART1) is one of the major mono-ADP-ribose transferases and has been shown 
to be involved importantly in many biological processes. DNA methylation is an important epigenetic mechanism 
in tumorgenesis.However, the influence of ART1 on DNA methylation contributing to this function in colorectal car-
cinoma cells remains unclear. The expression and activity of DNA methyltransferase 1 (DNMT1) was detected by 
western blotting. The binding between ART1 and DNMT1 was assessed by co-immunoprecipitation. The methylation 
status of uPA gene was determined by bisulfite sequencing PCR. DNMT1 expression and activity were increased as 
ART1 was silenced, and decreased as ART1 was over-expressed in CT26 colorectal carcinoma cells. The expression 
of DNMT1 decreased and uPA increased, respectively, following the treatment with 5-aza-2’deoxycytidine in GFP-
shART1 group. Invasion and metastasis were enhanced in GFP-shART1 group treated with 5-aza-dC. Similar regula-
tion of expression of DNMT1 and uPA were confirmed in Balb/c mice. This study revealed that silencing of ART1 
induced hypermethylation of uPA gene and over-expression causes hypomethylation. It probably relates to the feed-
back mechanism of NF-κB to PARP1 thus mediating the expression and activity of DNMT1. The relationship between 
ART1 and DNA methylation might offer a new therapeutic target for the improved treatment of this major cancer.
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Introduction
Colorectal carcinoma (CRC) is one of the most 
common tumors in a genetic view, yet it remains 
a major cause of cancer-caused death [1], indi-
cating that some CRC cells are resistant to cur-
rent therapies. CRC develops as a consequence 
of the accumulation of genetic alterations that 
activate proto-oncogenes. Epigenetic modifica-
tions, especially DNA methylation in certain 
gene promoters, are recognized as common 
molecular alterations in human tumors [2, 3].
DNA methylation is an important epigenetic 
event, in which DNA is modified by the enzymat-
ic conversion of certain cytosine residues to 
5-methylcytosine [4]. This methylation can cau- 
se changes in the structure of chromatin, and 
conformation and stability of DNA leading to 
changes in the interactions between DNA 
and proteins, thereby controlling the expre- 
ssion of genes. Furthermore, Davis et al report-
ed that it plays a significant role in maintaining 
cellular functions, and changes in the methyla-
tion status may contribute to the development 
of cancer [5]. The methylation reaction is 
catalyzed by DNA methyltransferases,helping 
to maintain the patterns of expressions of 
genes [6]. There are three types of methyl- 
transferase enzymes, DNMT1, DNMT3a and 
DNMT3b, together they maintain the DNA 
methylation status in mammals [6]. Among 
them, DNMT1 regulates maintenance methy- 
lation and DNMT3 isoforms are thought to be 
the “de novo” methyltransferases. Recent stu- 
dies suggest that DNMT1 seems to be more 
important than other methyltransferases. Huan 
X and Lan J et al reported that DNMT1 contains 
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a domain showing homology to the polybromo-1 
protein, which is thought to mediate protein-
protein interactions [6, 7]. Many of these inter-
actions are involved in transcriptional repres-
sion [6, 8]. It has been known that alterations 
in DNA methylation occur in cancer, including 
hypomethylation of oncogenes and hyper- 
methylation of tumor suppressor genes [9]. 
Hypermethylation and hypomethylation are two 
contrasting types of aberrant methylation sta-
tus. Previous studies have shown that hypo-
methylation activates certain genes that favor 
growth of tumors, increasing the metastatic 
and invasive potential of cancer cells [10, 11].
Over the past decades, research has sugge- 
sted that there may be a relationship between 
poly (ADP-ribosyl) transferase-1 (PARP1) and 
DNMT1 [12, 13]. It has been shown that 
PARP-1 can bind to the promoter of the DNMT1 
gene, resulting in the loss of expression of 
DNMT1 which leads to hypomethylation of 
genomic DNA [12]. Furthermore, Reale et al 
have reported that PARP1 can inhibit the activ-
ity of DNA methyltransferases by binding to 
DNMT1 to form the PARP1-DNMT1 complex 
[14]. PARP-1 and the DNA methylation pathway 
have been associated with the repression of 
oncogene expressions [12].
Mono ADP-ribosylation is a covalent enzymatic 
transfer of one ADP-ribose from NAD+ to 
specific amino-acid residues of acceptor pro-
teins; the modification is catalyzed by cellular 
ADP-ribosyltransferases and certain bacterial 
toxins [15]. In vertebrates, what are the key 
enzymes are the mono-ADP-ribosyltransferas-
es, also known as ARTs [16]. Only ART1, ART3, 
ART4 and ART5 have been verified in the human 
genome. Among the four human ARTs, ART3 
and ART4 lack the signature R-S-EXE se- 
quence, and it is still unknown whether they 
are catalytically active or not. Relatively, ART1 
and ART5 do contain the R-S-EXE motif. ART5 
has only been reported in humans but ART1 
has been reported in humans and mice [15, 
17]. Therefore, ART1 is the most relevant ART 
for study, owing to its localization and 
conformation.
PARP1 has been studied extensively in the con-
text of cancer compared to ART1, and is the 
target of the newly approved anti-cancer drug, 
although they are both included in the classifi-
cation of ADP-ribosylation. Our previous studies 
indicate that overexpression of PARP1 and 
ART1 may be associated with invasion and 
metastasis in colon cancer [18, 19]. Our team 
has also demonstrated that expression of 
PARP1 is regulated by ART1 in colon cancer. 
The proposed mechanism behind this effect 
may involve mono-ADP-ribosylation at arginine 
mediated by ART1. It is reported that inhibition 
of ART1 decreases the expression and activity 
of RhoA, which regulates NF-κB, and conse-
quently decrease the expression of PARP-1 [20, 
21]. Based on the findings that ART1 can act as 
one of the regulators of PARP1, we hypothesize 
that ART1 may be related to the expression and 
activity of DNMT1.
Urokinase plasminogen activator (uPA) is a 
member of the serine protease family that pro-
motes conversion of inactive zymogen plasmin-
ogen to its active form, plasmin, which is regu-
lated by growth factors, cytokines, and steroids 
[22]. Also, Pakneshan et al reported that uPA 
has some cancer-related functions and is 
involved in promoting invasion and metastasis 
of tumors [2, 23]. A previous study revealed 
that uPA was partially methylated in Ras-
transfected cells and expression of uPA was 
induced upon treatment of Rastransfectants 
with 5-aza-dc, an agent which diminished meth-
ylation of DNA [22]. Although it is a key media-
tor of the invasion and metastasis [24], it is still 
unclear what regulates the expression of uPA 
gene expression at different stages of tumor 
progression.
In this study, to determine the effect of ART1 on 
DNMT1 and on the methylation of uPA promot-
er regions in DNA, which may be an epigenetic 
mechanism that affects invasion and metasta-
sis of colorectal carcinoma, we silenced ART1 
in CT26 cells via transfection of a lentivirus-
based ART1-shRNA. Further, to verify the 
effect of ART1 on DNMT1, we used 5-aza-
2’deoxycytidine, an epigenetic modifier, which 
inhibits expression and activity of DNA methyl-
transferases causing DNA hypomethylation 
and over-expression of certain genes [25].
Materials and methods
Reagents
The CT26 cell line (a murine colon adenocarci-
noma cell line) was kindly provided by Professor 
Y-Q Wei, Sichuan University, China. CT26 
cells transfected with ART1-shRNA (ART1-
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shRNA), ART1-RNA and non-target shRNA (con-
trol-shRNA) have been previously established 
[26]. The experimental groups either over-
expressed ART1 in CT26 cells (GFP-ART1) or 
silenced expression of ART1 in CT26 cells (GFP-
shART1). Non-transfected CT26 cells and 
CT26 cells transfected with an empty lentivirus 
(GFP-vector) were used as control groups. 
DNMT-1 antibody was purchased from Abcam, 
Ltd. (Hong Kong). Rabbit anti-mouse uPA and 
rabbit anti-mouse β-actin antibody were pur-
chased from Boster Bioengineering Co. Ltd. 
(Wuhan, China), and polyclonal rabbit anti-
mouse ART1 antibody was purchased from 
Santa Cruz Biotechnology, Inc. (CA, USA). 
DL1,000 DNA Marker was obtained from 
TaKaRa Biotechnology, Co. Ltd., Dakian, (China). 
5-Aza-2’-deoxycytidine, from Sigma-Aldrich Co. 
(MO, USA), was dissolved into the concentra-
tion of 1 M in DMSO. DNeasy Blood&Tissue 
Kit was purchased from QIAGEN Group. EZ 
DNA Methylation-Gold Kit was purchased from 
Zymo Research Corp. BALB/c mouse were 
obtained from the Experimental Animal Center 
of the National Bio-industry Base in Chongqing, 
China.
Cell culture
CT26 cells (the GFP-shART1, GFP-ART1 and 
non-transfected cell lines) were cultured in 
RPMI-1640 medium (Hyclone, Logan, UT, USA) 
which was supplemented with 10% fetal bovine 
serum (FBS), 100 U/mL penicillin and 100 μg/
mL streptomycin (Hyclone) at 37°C in a 5% CO2 
incubator.
To confirm the effect of ART1 on DNMT1, chang-
ing the expression of uPA, CT26 cells were 
treated with 5Aza-dc. CT26 cells of the GFP-
shART1 group were cultured to 24 h before 
treatment. Cells were then treated with 5Aza-
dc (1 μM; Sigma) continuously for 72 h. 
Meanwhile, the medium was changed and the 
above treatment was repeated every 24 h. The 
dose of 5Aza-dc (1 μM) was chosen based on 
preliminary studies showing optimal reactiva-
tion of gene expression [25, 27].
Protein extract preparation
5×106 Cells which were washed twice with PBS 
were scraped to be collected into EP tubes and 
mouse spleen transplantation tumor tissues 
(100 mg) were extracted for total protein 
extract. The total protein extracts were pre-
pared with whole-cell protein lysis buffer 
(Beyotime, Shanghai, China). The suspensions 
centrifuged for 5 min at 5,000 rpm at 4°C in 
centrifuge tubes (Thermo Fisher Scientific, 
Waltham, UK). The supernatant solution was 
discarded and the pellets were lysed with lysis 
buffer for 30 min on ice. The total protein 
extract was obtained after centrifugation for 5 
min at 12,000 rpm and 4°C. Then the protein 
concentration was then assessed with a BCA 
protein assay kit (Beyotime, Shanghai, China).
Western blot analysis
Protein and pre-stained molecular weight 
markers were separated in a range of appropri-
ate voltage (80 V-100 V) by electrophoresis on 
10% SDS-polyacrylamide gels and were trans-
ferred onto polyvinylidene fluoride membranes 
(Millipore, Billerica, MA, USA). 5% Non-fat milk 
powder dissolved in TBST was incubated with 
the membranes for 2 h to be used to block het-
erogenetic antigen. After incubation, the mem-
branes were washed in TBST thrice and incu-
bated respectively overnight at 4°C with prima-
ry antibodies against DNMT1 (diluted 1:300), 
uPA and β-actin (diluted 1:500). After the incu-
bations with the primary antibodies, the mem-
branes were washed three times with TBST and 
then secondary antibody (peroxidase-conjugat-
ed goat anti-rabbit or rabbit anti-mouse IgG) at 
a dilution of 1:1000 were added and the mix-
tures were incubated for 2 h at room tempera-
ture. The blots were visualized with BeyoECL 
Plus (Beyotime) for exposure after the step of 
being washed three times with TBST. They were 
exposed and imaged in a luminoscope (BioRad).
The intensity of each band was analyzed with 
Quantity One software (BioRad). 
Cell migration assay 
A scratch wound assay was conducted to evalu-
ate cell migration of cells. 5×105 CT26 cells 
(GFP-shART1) were installed in six-well plates 
and cultured overnight to yield a confluent 
monolayer. Then a channel was scratched in 
the middle of each plate by 10 μL pipette tip 
and the displaced were washed away twice 
with PBS. The remaining cells were cultured 
with 0.5% FBS in RPMI1640 supplemented 
with 1 μM 5-Aza-dC. An equal volume to 5-Aza-
dC of PBS and RPMI1640 containing 0.5% FBS 
was used as a control medium. The cells were 
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examined and images were captured at 0 h and 
24 h using and NIS-Elements Image Analysis 
System (Nikon Corp., Tokyo, Japan) to measure 
the change of the width of the channel. The dis-
tances were marked at fixed intervals. Three 
independent measurements of the width of the 
wound were taken at random sites in each 
group and were used as statistical data. The 
mean values were calculated according to the 
following formula which determined the healing 
rate of the scratches.Healing rate: (initial 
scratch width value-corresponding points 
scratch width)/initial value ×100% scratch 
width.
Cell invasion assay (transwell)
A Transwell Matrigel invasion assay was used 
to evaluate invasion by cells. The upper cham-
ber above the polycarbonate membrane was 
paved with Matrigel (Becton, Dickinson and 
Company) and CT26 cells of GFP-shART1 (105/
well) were suspended in RPMI-1640 were seed-
ed. These cells were incubated with CT26-
conditioned supernatant (5-Aza-dC 1 µM in 
serum-free RPMI-1640. An equal volume to 
5-Aza-dC of PBS and RPMI-1640 without 
 serum served as a control). The lower chamber 
was filled with 500 µL RPMI-1640 supple- 
mented with 10% FBS. Cells were incubated for 
24 h and fixed using 4% paraformaldehyde. 
Then the number of cells in each well that 
migrated to the lower chamber was counted 
after staining with crystal violet. The rate of 
invasive inhibition was measured as follows: 
invasion inhibition rate = (averagetreated group 
- average untreated control group)/average 
value for the dosing control group ×100%.
Bisulfite sequencing PCR
Genomic DNA was obtained from CT26 cell 
lines using the DNeasy Blood&Tissue Kit 
(QIAGEN Group) in accordance with the manu-
facturer’s instructions. Sodium bisulfite modifi-
cation of genomic DNA was performed with 
the EZ DNA Methylation-Gold Kit (Zymo Re- 
search, Corp). In order to evaluate the methyla-
tion status of the CpG islands of the putative 
uPA promoter region, one set of bisulfite 
sequencing primers was designed. The primers 
B-uPA-F (5’-GGGATAGGTTGGAGAAGAATTG-3’) 
and B-uPA-F (5’-TTCCTTTTCCTACATCCCACC-3’) 
were applied to amplify the CpG islands in the 
promoter region with the preparatory DNA prod-
uct 254 bp in length. Following this, BSP ampli-
fications were conducted in 50 µL reaction mix-
tures containing 3 µL bisulfite-modified genom-
ic DNA, 1 µL dNTPs, 1 µL primers F, 1 µL prim-
ers R, 5 µL Taq Buffer (100 mM Tris-HCl (pH 
8.8 at 25°C), 500 m MKCl, 15 mM MgCl2, 0.8% 
(v/v) Nonidet P40), 0.8 µL Taq polymerase 
and 38.2 µL H2O, in an American ABI PCR sys-
tem verity 96-well plate. The PCR cycling condi-
tions applied to amplify the promoter region 
were as follows: 98°C denaturing for 4 min; 
94°C for 45 sec, annealing temperature 66°C 
for 45 sec, 72°C for 1 min, each temperature 
cycle repeated twice; 94°C denaturing for 45 
sec, 56°C annealing for 45 sec, 72°C for 1 
min, repeated 20 times, 72°C 8 min. Then 
PCR products were analyzed by 3.0% electro-
phoresis on a 3.0% agarose gel and staining 
with ethidium bromide followed by visuali- 
zation with ultraviolet illumination. Purified PCR 
purified products were cloned into pUC18-T 
(Sangon Biotech Company, Shanghai, China) as 
described by the manufacturer in 10 µL reac-
tion mixtures containing 1 mL 10× Ligation 
Buffer, 1 mL 50% PEG, 50 ng pUCm-T Vector, 
0.2 pmol PCR product and 2.5 U T4 DNA Ligase. 
Afterwards, five individual clones were se- 
quenced in the use of the M13 primer.
Co-Immunopreciptation
Purchased cells were lysed on ice in RIPA buffer 
(Beyotime) for 15 min. After the lysates had 
been centrifuged at 14000 rpm at 4°C for 15 
min, the supernatant solutions which contained 
proteins were collected and then incubated 
with primary antibodies of ART1 (1:200 dilu-
tion) for 2 h at room temperature. To capture 
the antibody-analyte complex, protein A+G 
agarose (Beyotime) of 100 µL were incubated 
with the supernatants mentioned above over-
night at 4°C. Agarose-antibody-analyte com-
plexes were gathered by being centrifuged at 
the speed of 14000 rpm for 5 sec and were 
washed with PBS for trice and then regained 
with 1× SDS-PAGE buffer in boiling water bath 
for 5 min. Western blotting was used for the 
analysis of immunoprecipitations with the anti-
bodies against ART1 and DNMT1. All experi-
ments were performed in triplicate.
Model of transplantation tumor
6-to-8-week-old female BALB/c mice (18-22 g) 
were purchased from the Animal Center of 
Chongqing Medical University. All experimental 
procedures were conducted in conformity with 
institutional guidelines for the care and use of 
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laboratory animals in the Institutional Animal 
Care and Use Committee of Chongqing Medical 
University and conformed to the Chinese 
Science Institutes of Health Guide (Animal 
Welfare Act). To verify whether these molecular 
mechanisms in vivo is in accordance with 
those in vitro, four groups (GFP-shART1, GFP-
ART1, GFP-vector and non-transfected groups) 
of CT26 cells (2×106) were administered to 
BALB/c mice respectively.The growth of tumors 
was observed daily.The mice were then execut-
ed to allow collection of the subcutaneous 
transplanted CT26 carcinoma at the 14th day.
The isolated protein of these tumor tissues was 
extracted for Western blotting analysis.
To detect the effect of ART1 silencing on DNA 
methylation and the metastasis of the colon 
carcinoma in vivo, 2% chloral hydrate (0.3 g/
Kg) was injected i.p. to the mice, and then GFP-
shART1 CT26 cells (5×105) were injected into 
the spleen capsule of BALB/c mice. When the 
size of the tumor grew to 10 d after injection, 
the mice of the experimental group were in- 
jected with 5-aza-dc (1.0 µg/g dissolved in 100 
µL PBS) every week up to 3 times [28]; and the 
mice of the control group were injected with 
100 µL PBS. The weight of the transplanted 
tumor was measured and the liver metastasis 
nodules were calculated when mice were sacri-
ficed at the 28th day. The sizes of the tumors 
were measured and calculated volumes (V = 
ab2/2; a, the longest diameter; b, the shortest 
diameter). The liver metastases were assessed 
according to the number of metastatic nodules 
on the liver and the total liver weight [29]. 
Excised transplanted tumors (about 100 mg) 
of the spleen were used to extract total protein 
for Western blot investigations.
Statistical analysis
The results from western-blotting and RT-PCR 
were presented as the means ± standard devi-
Figure 1. ART1 silencing induces the expression of DNMT1 and reduces the uPA expression in vitro and in vivo. A 
and C. Protein levels of non-transfection, GFP-shART1, GFP-ART1 and GFP-vector group in vitro and in vivo were de-
termined by western blotting and images are shown representatively. B and D. Quantification of protein levels was 
performed by densitometry. Results represent the mean +/- SD of the expression levels from three independent 
experiments standardized to β-actin expression and normalized to 100% in untransfected cells. The expression of 
DNMT1 is statistically increased in GFP-shART1 group and decreased in GFP-ART1 group compared to other groups 
(P<0.01), while the expression of uPA is statistically decreased in GFP-shART1 group (P<0.01 in vitro and P<0.05 in 
vivo) and increased in GFP-ART1 group (P<0.01 in vitro and in vivo) relative to the expression in untransfected and 
GFP-vector groups.
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ation (SD). Differences between different 
groups were analyzed with one-way ANOVA and 
the Wilcoxon test and correlation analysis was 
taken into use with Spearman’s correlation 
analysis in SPSS 18.0 software (SPSS, Chicago, 
IL, USA). A probability value of P<0.05 was con-
sidered to illustrate a statistically significant 
difference.
Results
Effects of ART1 on expression of DNMT1 and 
uPA in vitro and in vivo
In order to explore whether ART1 affects the 
expression of DNMT1 and uPA in colon carci-
noma, Western blotting was used to examine 
the expression of related proteins on the level 
of protein in vitro and in vivo. The expression 
of DNMT1 was increased in GFP-shART1 
(P<0.01) and decreased in GFP-ART1 group 
compared to the control and untransfected 
groups in vitro and in vivo (P<0.01). Conversely, 
decreased expression of uPA in GFP-shART1 
group (P<0.05) and increased expression in 
GFP-ART1 group (P<0.01) were shown com-
pared to other groups (Figure 1).
Inhibition of DNA methylation regulates the ex-
pression of DNMT1 and uPA in vitro and in vivo
In order to verify the effect of ART1 on methyla-
tion of the uPA promoter and expression of uPA, 
the GFP-shART1 group was treated with 5-aza-
Figure 2. The effect of DNA methylation inhibition on the expression of uPA and DNMT1 in vitro and in vivo. A. CT26 
cells were treated with 1 µM of the DNA methylation inhibitor 5-aza-dC in GFP-shART1 group every 24 h for 3 days. 
Protein levels were detected by western blotting. Images are shown representatively. C. After GFP-shART1 CT26 cells 
(5×105) were injected into the Balb/c mice, 1 µg/g 5-aza-dC were given to them every week up to 3 times. And the 
commensurable protein of subcutaneous transplanted tumor was extracted for the western blotting analysis at the 
28th day. Protein levels of GFP-shART1 with 5-aza-dC and GFP-shART1 group were detected by western blotting and 
images are shown respectively. B and D. Quantification of protein levels was performed by densitometry. Results 
represent the mean +/- SD of the expression levels from three independent experiments standardized to β-actin 
expression. The expression of DNMT1 is statistically decreased in GFP-shART1 with 5-aza-dC group compared to 
the other group (P<0.01 in vitro and P<0.05 in vivo), while the expression of uPA is statistically increased (P<0.01 
relative to the expression in GFP-shART1 group).
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Figure 3. Effects of ART1 on the DNA methylation status of uPA gene promoter region in vitro. (A) Representative bisulfite sequencing results of uPA gene in CT26 
cells were detected by BSP sequencing results that mean methylation status of GFP-ART1, GFP-vector, non-transfection and GFP-shART1 group are shown respec-
tively as (a-d). (B) Methylation is indicated in red. Open and filled circles stand for unmethylated and methylated CpG sites, and each row stands for a single clone 
(a-d represent GFP-ART1, GFP-vector, non-transfection and GFP-shART1 group).
ART1 and DNA aberrant methylation
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dc (1.0 μM, 72 h). Western blotting was used to 
test the expression of DNMT1 and uPA in vitro 
and in vivo. It was showed that the expression 
of DNMT1 was reduced in the GFP-shART1 
group with 5-aza-dc compared to the control 
GFP-shART1 group in vitro (P<0.01) and in vivo 
(P<0.05). There was an increase of the expres-
sion of uPA in the GFP-shART1 group with 
5-aza-dc in contrast to control GFP-shART1 
group in vitro and in vivo (P<0.01) (Figure 2).
Effects of ART1 on the DNA methylation status 
of uPA gene promoter region in vitro
To investigate further the influence of ART1 on 
DNA methylation of the putative uPA promoter 
regions, Bisulfite sequencing PCR of genomic 
DNA was applied. It showed that the DNA meth-
ylation status of uPA were 55.7%, 27.1%, 42.9% 
and 42.9% in GFP-shART1, GFP-ART1, non-
transfection and GFP-vector groups respective-
ly. Compared with non-transfection and GFP-
vector group, the DNA methylation status of 
uPA showed an increase in the GFP-shART1 
group (P<0.05), while there was a clear reduc-
tion of uPA methylation status in the GFP-ART1 
group (P<0.05; Figure 3).
Relationship between ART1 and DNMT1 in 
vitro
Co-immunoprecipitation showed that there is 
no direct binding interaction between ART1 and 
DNMT1 (Figure 4).
Figure 4. DNMT1 has no interact with ART1 in CT26 cells. Western blot analysis of the co-IP complex following incu-
bation of GFP-ART1, Non-transfection and Vector CT26 cells lysates with ART1 antibody. DNMT1 was not detected in 
IP product of GFP-ART1 and Non-transfection group. NC; negative control group used IgG instead of ART1 antibody 
to incubate the lysate of GFP-ART1 CT26 cells.
Figure 5. Effect of DNA methylation inhibitor on CT26 cells migration. A. GFP-shART1 CT26 cells were treated with 
an inhibitor 5-aza-dC as the experimental group. The control group was the GFP-shART1. Cell migration assay was 
taken to detect migration capacity. Representative images are shown above. a and c. Control group at 0 and 24 h, 
respectively. b and d. 5-Aza-dC treated group at 0 and 24 h, respectively. B. GFP-shART1 group treated with 5-aza-
dC significantly pushed CT26 cells to heal the wound. The migration distance for 24 h in GFP-shART1 with 5-aza-dC 
treated group was greater than that of the GFP-shART1 group (P<0.01).
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Effects of DNA methylation inhibition on inva-
sion and migration of GFP-shART1 CT26 cells 
in vitro
The cell migration assay was used to detect 
the migration capacity of CT26 cells. In the 
preparatory work, GFP-shART1 cells were treat-
ed with an inhibitor of DNMT1 (5-aza-dc). The 
results showed that the GFP-shART1 group 
treated with 5-aza-dc significantly stimulated 
CT26 cells to heal the wound and the mig- 
ration distance for 24 h was increased com-
pared to the GFP-shART1 group (P<0.01; Figure 
5).The invasion capacity of CT26 cells was 
detected by the Transwell assay. The number of 
CT26 cells that underwent invasion through 
Matrigel in the 5-aza-dc treated group was 
67.3±3.5. The number of cells invading in the 
untreated control group was 34.3±3.2. The val-
ues were significantly higher in the 5-aza-dc 
treated group than those in the control group 
(P<0.01; Figure 6).
Effects of DNA methylation inhibition on liver 
metastasis of GFP-shART1 CT26 cells in vivo
To verify the positive effect of DNA methylation 
inhibition on invasion and metastasis of CT26 
cancer cells, the liver metastasis model was 
created in BALB/c mice by injecting CT26 cells 
(GFP-shART1) into the splenic capsule. The 
mice of the experimental group then were treat-
ed with 5-aza-dc. The neoplasm was gray and 
hard. Necrosis was found in some parts of the 
tumor whose boundaries were clear to the 
neighbouring tissues. Livers contained multi-
ple, coalescing pale nodules (0.2-0.5 cm). The 
histological feature of different treatment 
groups showed that cancer cells were arranged 
in sheets, round or oval. The cell nucleus was in 
deep colour with obvious atypia. And pathologi-
cal karyokinesis could be observed. Compared 
to the controlled group, the weight of the liver 
was much higher in the experimental group 
(P<0.05). Meanwhile the number of liver metas-
tasis nodules showed a significant increase in 
experimental group (P<0.01), compared with 
the control group. Therefore, these results 
strongly supported our previous theory that 
inhibition of DNA methylation could enhance 
the metastatic capacity of CT26 cells in vivo 
(Figure 7; Table 1).
Discussion
As Partha et al have informed, DNA methylation 
is a significant regulator of the transcription of 
genes, and its function in carcinogenesis has 
been a topic of debate for years [30]. In the cur-
rent view, DNA methylation has a crucial role in 
the development of cancers. In more specific 
terms, hypermethylation leads to silencing of 
genes through repressing transcription of the 
promoter regions of tumor suppressor genes, 
while hypomethylation causes growth of the 
tumor through activating oncogenes [30].
Therefore, mediators of DNMT1 are of impor-
tance. It has also been reported that PARP1 
could mediate the expression and activity of 
DNMT1 through non-covalent interactions [14].
In mammalian cells, both mono (ADP-ribosyl)
ation and poly (ADP-ribosyl) ation reactions are 
regulated by enzymes that can reverse these 
posttranslational modifications [31]. In our pre-
vious study, we have demonstrated that inhibi-
Figure 6. Effect of DNA methylation inhibition on CT26 cells invasion. A. GFP-shART1 CT26 cells were treated with 
an inhibitor 5-aza-dC as the experimental group. The control group was the GFP-shART1. The invasion capacity was 
detected by transwell assay (crystal violet staining). Representative images are shown. a. Control group; b. 5-Aza-
dC treated group. B. The CT26 cells number that migrated to Chambers membrane in experimental group was 
greater than that of control group. (P<0.05 relative to control group from three independent experiments).
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tion of PARP1 decreases invasion and the met-
astatic ability of colon cancer cells [19]. 
Similarly, silencing of ART1 decreases invasion 
and the metastatic ability of colon cancer cells 
through down-regulating the expression of 
RhoA, Rock1, MMP-2 and MMP-9 [18]. In addi-
tion, it has been shown that PARP1 could be 
regulated by ART1 possibly via affecting the 
expression and activity of RhoA and NF-κB [21].
Meanwhile, Caiafa et al demonstrated that 
polymers present on PARP1 bind to DNMT1 
non-covalently to decrease its expression and 
activity [13]. As we hypothesized above, wheth-
er ART1 could regulate DNMT1 remained 
unknown. However, there were no data avail-
able to indicate some correlation between 
ART1 and DNA methylation in colon carcinoma.
Thus, in this study, we examined the expression 
of DNMT1 following the transfection of CT26 
cells with GFP-shART1 and GFP-ART1 to eluci-
date the correlation between ART1 and DNMT1 
in colon carcinoma. The results revealed that 
inhibition of ART1 could induce the expression 
of DNMT1 and over-expression of ART1 could 
decrease it in colon carcinoma. The DNA meth-
yltransferases are available to catalyze the pro-
cess of DNA methylation,and their expression 
and activity are closely associated with the sta-
tus of DNA methylation. To confirm further the 
effect of ART1 on DNA methylation status,we 
used bisulfite sequencing PCR [32, 33] to mea-
sure the exact methylation status of certain 
genes. We chose the uPA gene to detect meth-
ylation status of its promoter regions. The uro-
kinase plasminogen activator (uPA) is one of 
the proteases which are associated with the 
invasiveness of tumors and is involved in cellu-
lar migration by interacting with vitronectin 
and integrins [34]. Consistent with the results 
of expression of DNMT1, hypermethylation 
through silencing of ART1 and hypomethylation 
of uPA with ART1 over-expression were detect-
ed relative to controls. It was previously dis-
cussed that uPA expression was regulated by 
DNA methylation as reported by Guo et al [34, 
35]. Pakneshan et al reported that up-regula-
tion of DNMT1 caused silencing of uPA and inhi-
bition of invasion and metastasis of breast can-
cer cells [34, 36, 37]. Thus we measured the 
Figure 7. Effects of DNA methylation inhibition on liver 
metastasis of CT26 cells in vivo. A. The liver metastasis 
model of BALB/c mice was created via injecting CT26 
cells into splenic capsule. a. 5-Aza-dC treated group; b. 
Control group. B. Compared to the control group, liver 
weight was much higher in experimental group (P<0.05) 
as images shown above. C. In order to detect the migra-
tion level, the liver metastasis nodules were numbered. 
The number of liver metastasis nodules showed signifi-
cant increase in experimental group (P<0.01), compared 
with the controlled group. Then liver weight and the liver 
metastasis nodules were respectively shown in Table 1.
Table 1. Liver weight and the liver metastasis 
nodules were respectively shown below (SD 
± s, n=5)
Group Liver weight (g)
Liver metastasis 
nodule number
5-aza-dC-treated 1.08±0.10 6.67±3.51
Untreated control 0.77±0.16 0.53±0.04
The number of liver metastasis nodules showed signifi-
cant increase in experimental group compared with the 
controlled group (P<0.05). The liver weight of 5-aza-dC 
treated group was higher than that of the untreated 
control group (P<0.01).
ART1 and DNA aberrant methylation
4279 Int J Clin Exp Pathol 2016;9(4):4269-4282
expression of the gene, and our results revealed 
that inhibition of DNMT1, which may cause 
hypomethylation of uPA promoters, brought 
about up-regulation of uPA gene expression in 
mouse CT26 cells, and increasing of DNMT1 
might cause the opposite effect. Therefore, we 
could initially conclude that ART1 might induce 
aberrant methylation status of the uPA promot-
er so as to regulate the expression of uPA which 
could participate in the progresses of tumor 
invasion and metastasis.
From the current findings, it may be reasonable 
to hypothesize that there might be two explana-
tions for the effect of ART1 on DNMT1. On one 
hand, just as there is a relationship between 
PARP1 and DNMT1, ART1 might have interac-
tion with DNMT1 thus causing its expression 
and regulating its activity. On the other hand, 
their interaction might be not direct but through 
some regulatory pathway. We confirmed the for-
mer situation and demonstrated that ART1 and 
DNMT1 have no direct interaction between 
them. In a previous study, we demonstrated 
that the expression of PARP1 could be mediat-
ed by ART1 in mouse colorectal carcinoma 
CT26 cells [21]. We also reported that inhibition 
of ART1 could decrease the expression and 
activity of RhoA, which stands downstream of 
the mono (ADP-ribosyl) ation regulated by ART1 
[20]. Yau et al pointed out that MIBG (meta-
iodobenzylguanidine, an inhibitor of ART1) can 
inhibit the Rho effector, implying the participa-
tion of mono (ADP-ribosyl) ation in a Rho-
dependent signaling pathway [38]. Among the 
Rho proteins, RhoA can regulate NF-κB-
dependent transcription [39]. It is also revealed 
by Huang et al that inhibition of RhoA could 
downregulate the NF-κB through the decrease 
of phosphor-IκBα in prostate carcinoma cells 
[40]. We have previously demonstrated that 
inhibition of NF-κB could downregulate the 
expression of PARP1 through a feedback mech-
anism [41]. MIBG which contemporaneously 
downregulates the expression of PARP1 and 
ART1 to clarify the effect between ART1 and 
PARP1. Therefore, we conclude that ART1 may 
mediate expression of PARP1 by mediating the 
expression and activity of RhoA, thus regulating 
NF-κB-dependent transcription. Meanwhile, 
some reports suggested a link between PARP-1 
and DNMT1. In their model, PARP1 could pre-
vent the enzymatic activity of DNMT1 through 
non-covalent protein-protein interactions [13]. 
Similarly, it has been demonstrated that PARP-
1 binds to the promoter of the DNMT1 gene 
and affects DNA methylation status by regulat-
ing the expression and activity of the DNMT1 
[12]. Hence it could be concluded that the 
expression of PARP1 was probably regulated by 
ART1 through the feedback mechanism of 
NF-κB to PARP1 thus mediating the expression 
and activity of DNMT1 through non-covalent 
interactions. And in our current study, we used 
an inhibitor of DNA methyltransferase (5-aza-
dc) in the GFP-shART1 group and observed how 
the expression of uPA changed. Expression of 
uPA increased upon treatment with the demeth-
ylating agent 5-aza-dc in the GFP-shART1 
group. Then we tested the capacity for invasion 
and metastasis, a significant increase was 
shown. And according to some studies, DNMTs 
could be inhibited by 5-aza-dc in cancer cells. 
In detail, DNMT1 was nearly all inhibited while 
DNMT3a and DNMT3b was part of losing the 
activity [42]. It meant that 5-aza-dc had the 
most effective inhibition on DNMT1 among 
DNMTs. Some reports also suggested that the 
decrease of DNMT1 could cause DNA hypo-
methylation of certain cancer-related genes 
[13]. Therefore, it could be concluded that inhi-
bition of DNMT1 might be related to CT26 cells 
migration motility. In our previous study, we 
have demonstrated that inhibition of ART1 
could decrease invasion and metastatic ability 
in mouse CT26 cells [18]. Therefore, as there is 
a relationship between ART1 and DNMT1, the 
effect of DNMT1 on cancer invasion and metas-
tasis could be mediated by ART1. Altogether, 
ART1 might participate in invasion and metas-
tasis in mouse CT26 cells through the ART1-
DNMT1 pathway.
The above conclusions have been translated 
effectively in vivo in our BALB/c mice models. 
5-aza-dc was applied to the experimental 
group, causing hypomethylation of uPA gene 
promoters and then over-expression of uPA 
[43]. Opposing effect of 5-aza-dc on growth 
and invasion of tumors has been reported [25], 
an issue which remains to be resolved.
In summary, the novelty of the present work is 
that it not only elaborates how PARP1 is medi-
ated by ART1 but also reveals ART1 causes 
aberrant methylation of the uPA promoter.It 
probably related to PARP1-DNMT1 complex,thus 
participating in tumorigenesis. Although further 
ART1 and DNA aberrant methylation
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studies may be required,the data presented 
here offered a dependable mechanism for 
ART1 mediating DNMT1 in colon cancer cells.
We expect that our study may be a new 
approach to clarifying ART1 in the ART1-DNMT1 
pathways as a promising therapeutic strategy 
for colorectal carcinoma.
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